The influence of SGLT2 inhibitors on the risk of urinary tract infection in patients with type 2 Diabetes Mellitus: an integrative literature review
DOI:
https://doi.org/10.15343/0104-7809.202549e17482025PKeywords:
SGLT2 Inhibitors, Urinary Tract Infection, Type 2 Diabetes MellitusAbstract
The objective of the present study was to gather information on the influence of Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i) on the risk of developing urinary tract infection (UTI) in patients with type 2 Diabetes Mellitus (T2DM). This is an Integrative Literature Review (ILR) that collected data from the following databases: Virtual Health Library (VHL) and the National Library of Medicine (PubMed). Inclusion criteria were: articles published between 2020 and 2024, in English, Portuguese, or Spanish, free of charge and available in full text. Exclusion criteria included: articles outside the scope of the topic, duplicates, paid-access publications, and monographs. A total of 73 articles were identified, of which 10 remained after selection and analysis using Zotero software. The included studies indicated an association between SGLT2i use and an increased risk of UTI and urogenital infections, mainly related to dapagliflozin, remogliflozin, and glycosuria. Factors such as higher body mass index and female sex play a more relevant role in UTI predisposition than the isolated use of these drugs. Despite the divergences, the benefits of SGLT2 inhibitors outweigh the potential risks, and their use remains recommended, provided that adequate professional supervision is ensured.
Downloads
Translations of this article
References
Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front Public Health. 27 de julho de 2022;10:888205.
Kaur R, Kaur R. Symptoms, risk factors, diagnosis and treatment of urinary tract infections. Postgraduate Medical Journal. 1o de dezembro de 2021;97(1154):803–12.
Timm MR, Russell SK, Hultgren SJ. Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics. Nat Rev Microbiol. fevereiro de 2025;23(2):72–86.
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. The American Journal of Medicine. julho de 2002;113(1):5–13.
Jia H, Su W, Zhang J, Wei Z, Tsikwa P, Wang Y. Risk factors for urinary tract infection in elderly patients with type 2 diabetes: A protocol for systematic review and meta-analysis. Kokori E, organizador. PLoS ONE. 26 de setembro de 2024;19(9):e0310903.
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. janeiro de 2019;62(1):3–16.
Salari N, Karami MM, Bokaee S, Chaleshgar M, Shohaimi S, Akbari H, et al. The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis. Eur J Med Res. 5 de fevereiro de 2022;27(1):20.
Nunes CP, Giusti CT. EFICÁCIA E EVENTOS ADVERSOS DOS INIBIDORES DE SGLT2. Revista da Faculdade de Medicina de Teresópolis. 15 de dezembro de 2020; 4(1):14-21.
Hsu TL, Liu FH, Sun JH, Lin YH, Tsai CY, Lin CH. Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study. Endocrine Practice. maio de 2025;31(5):592–8.
De Sousa MNA, Bezerra ALD, Do Egypto IAS. Trilhando o caminho do conhecimento: o método de revisão integrativa para análise e síntese da literatura científica. OLEL. 24 de outubro de 2023;21(10):18448–83.
Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare: a guide to best practice. 3a ed. Philadelphia: Wolters Kluwer/ Lippincott Williams & Wilkins; 2011.
Li CX, Liu LY, Zhang CX, Geng XH, Gu SM, Wang YQ, et al. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). setembro de 2023;14:1238399– 1238399.
Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, et al. Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. 2023;46(2):175–93.
P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra State, India, Ferwani P, Maldar A, Shah N, Shah P, Chadha M. Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study. JAFES. 25 de novembro de 2022;37(2):5–8.
Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MW, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort Study. Canadian Journal of Diabetes. junho de 2022;46(4):392-403.e13.
Iordan L, Avram VF, Timar B, Sturza A, Popescu S, Albai O, et al. Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice-A Cross-Sectional Study. Medicina (Kaunas). 1o de dezembro de 2024;60(12):1974.
Mashraqi MM, Chaturvedi N, Alam Q, Alshamrani S, Bahnass MM, Ahmad K, et al. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs. Molecules. 22 de janeiro de 2021;26(3):582.
Ueda M, Zenibayashi M, Yamada T, Asahara SI, Ogawa W. Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors. Kobe J Med Sci. agosto de 2024;70(3):E81–8.
Chen L, Xue Q, Yan C, Tang B, Wang L, Zhang B, et al. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Front Endocrinol (Lausanne). novembro de 2023;14:1256548–1256548.
Tanriverdi M, Bastemir M, Demirbakan H, Ünalan A, Türkmen M, Tanriverdi GÖ. Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocr Disord. outubro de 2023;23(1):211–211.
Lin DSH, Lee JK, Chen WJ. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. J Clin Endocrinol Metab. 2021;106(7):2133–45.
Benjamin T, Schumacher C. Characterization of Risk Factors for Genitourinary Infections with Sodium‐Glucose Cotransporter‐2 Inhibitors. Pharmacotherapy. outubro de 2020;40(10):1002–11.
Anan G, Kikuchi D, Omae K, Hirose T, Okada K, Mori T. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database. Endocr J. 2023;70(11):1103–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 O Mundo da Saúde
This work is licensed under a Creative Commons Attribution 4.0 International License.
